Clinical trial NCT02452632: A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin
Official title: A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-group, Placebo-Controlled Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Type 2 Diabetes Mellitus
Keywords: ASP1941
Type 2 diabetes mellitus
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
First posted: 2015-05-22
Enrollment: 143
Sex: ALL
Minimum age (years): 19
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the efficacy and safety of ASP1941 50mg once daily in combination with metformin and sitagliptin against placebo in combination with metformin and sitagliptin over a 24 week treatment period in subjects with type 2 diabetes mellitus with inadequate glycemic control on metformin and sitagliptin.


Eligibility criteria: Inclusion Criteria:

* Subject has been diagnosed with type 2 diabetes mellitus.
* Subject has an HbA1c value between 7.0% and 10.5 % at visit 1.
* Subject shows FPG (Fasting Plasma Glucose) value is less than 270mg/dL.
* Subject shows a BMI of 20.0 to 45.0 kg/m2.
* Subject is on stable diet and exercise program at least 8 weeks prior to study participation.
* Postmenopausal female or surgically sterile female or agree not to become pregnant.

Exclusion Criteria:

* Subject has type 1 diabetes mellitus.
* Subject has proliferative diabetic retinopathy.
* Subject has a history of clinically significant renal disease(s) such as renovascular occlusive disease, nephrectomy, or renal transplant.
* Subject has significant dysuria caused by a neurogenic bladder or a benign prostatic hypertrophy etc.
* Subject has a symptomatic urinary tract infection or genital infection.
* Subject has chronic disease(s) that require the continuous use of systemic corticosteroids or immunosuppressants.
* Subject has cardiovascular disease or cerebrovascular disease that may affect the administration of ASP1941 or its safety assessment in the opinion of the investigator or sub-investigator.
* Subject has uncontrollable psychiatric disorder(s) with medication.
* Male subject is not willing to use appropriate contraception during the study.
* Subject has severe infection, serious trauma, or perioperative subject.
* Subject has a malignant tumor or has a history of malignant tumor.
* Subject has severe gastrointestinal disease, or history of operation for serious gastrointestinal disease.
* Subject has diabetic ketoacidosis.
* Subject has lactic acidosis or has history of lactic acidosis.
* Subject has hepatitis or is a carrier of hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or is positive for HIV-1 and/or HIV-2.
* Subject has a history of thyroid dysfunction and acute pancreatitis.
* Subject is on weight-loss program or weight-loss medication (e.g. orlistat, phentermine/topiramate, lorcaserin) within 12 weeks of study participation.
* Subject has a history of serious cardiac diseases (NYHA Class III to IV), congestive heart failure, arrhythmia in need of medical treatment.
* Subject has a history of cerebrovascular attack, unstable angina, myocardial infarction, angioplasty, within 52 weeks (364 days) of study participation.
* Subject has uncontrollable severe hypertension, i.e., systolic blood pressure of higher than 180 mmHg or diastolic blood pressure of higher than 110mmHg measured in a sitting position after a 5-minute rest.
* Subject has following AST or ALT value:

  * AST: Male \> 100 U/L, Female \> 80 U/L
  * ALT: Male \> 102.5 U/L, Female \> 82.5 U/L
* Subject has following serum creatinine value:

  * Creatinine: Male \> 1.3 mg/dL, Female \> 1.2 mg/dL
* Subject has estimated GFR values, of \< 60 mL/min/1.73m2.

Primary outcomes:
measure: Change from baseline in HbA1c at the end of treatment
timeFrame: at 24 weeks
Secondary outcomes:
measure: Change from baseline in Fasting plasma glucose at the end of treatment
timeFrame: at 24 weeks
measure: Change from baseline in Fasting serum insulin at the end of treatment
timeFrame: at 24 weeks
measure: Change from baseline in Body weight at the end of treatment
timeFrame: at 24 weeks
measure: Change from baseline in Waist circumference at the end of treatment
timeFrame: at 24 weeks
measure: Safety assessed by development of adverse events, vital signs, laboratory tests, and 12-lead ECG
timeFrame: up to 24 weeks
measure: Number of subjects achieving the target HbA1c(<6.5% and <7.0%) at each visit
timeFrame: at 4, 8, 12, 16 and 24 weeks
measure: Percentage of subjects achieving the target HbA1c(<6.5% and <7.0%) at each visit
timeFrame: at 4, 8, 12, 16 and 24 weeks
Other outcomes:
Locations:
city: Busan
country: Korea, Republic of
facility: Site KR00002
city: Busan
country: Korea, Republic of
facility: Site KR00003
city: Daegu
country: Korea, Republic of
facility: Site KR00007
city: Daegu
country: Korea, Republic of
facility: Site KR00011
city: Dong Gu Gwangju
country: Korea, Republic of
facility: Site KR00019
city: Gangwon-do
country: Korea, Republic of
facility: Site KR00008
city: Gyeonggi-do
country: Korea, Republic of
facility: Site KR00018
city: Gyeonggi-do
country: Korea, Republic of
facility: Site KR00022
city: Incheon
country: Korea, Republic of
facility: Site KR00014
city: Jeollabuk-do
country: Korea, Republic of
facility: Site KR00020
city: Kyungsangnam-do
country: Korea, Republic of
facility: Site KR00021
city: Seoul
country: Korea, Republic of
facility: Site KR00001
city: Seoul
country: Korea, Republic of
facility: Site KR00004
city: Seoul
country: Korea, Republic of
facility: Site KR00005
city: Seoul
country: Korea, Republic of
facility: Site KR00006
city: Seoul
country: Korea, Republic of
facility: Site KR00009
city: Seoul
country: Korea, Republic of
facility: Site KR00010
city: Seoul
country: Korea, Republic of
facility: Site KR00012
city: Seoul
country: Korea, Republic of
facility: Site KR00013
city: Seoul
country: Korea, Republic of
facility: Site KR00016
city: Seoul
country: Korea, Republic of
facility: Site KR00017
city: Suwon
country: Korea, Republic of
facility: Site KR00015
Study officials:
affiliation: Astellas Pharma Korea, Inc.
name: Medical Director
role: STUDY_DIRECTOR
References:
citation: Kashiwagi A, Shestakova MV, Ito Y, Noguchi M, Wilpshaar W, Yoshida S, Wilding JPH. Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials. Diabetes Ther. 2019 Dec;10(6):2201-2217. doi: 10.1007/s13300-019-00699-8. Epub 2019 Oct 12.